This HTML5 document contains 84 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n14http://linked.opendata.cz/resource/AHFS/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00259/identifier/kegg-compound/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00259/identifier/bindingdb/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00259/identifier/pdb/
foafhttp://xmlns.com/foaf/0.1/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00259/identifier/pubchem-compound/
n25http://linked.opendata.cz/resource/mesh/concept/
n5http://linked.opendata.cz/resource/drugbank/company/
n29http://linked.opendata.cz/resource/drugbank/dosage/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00259/identifier/pubchem-substance/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00259/identifier/drugbank/
n30http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n16http://linked.opendata.cz/resource/drugbank/drug/DB00259/identifier/national-drug-code-directory/
n28http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n26http://linked.opendata.cz/resource/drugbank/medicinal-product/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00259/identifier/chemspider/
n24http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n7http://www.drugs.com/cdi/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00259/identifier/chebi/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n10http://linked.opendata.cz/ontology/sukl/drug/
n11http://linked.opendata.cz/resource/atc/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00259/identifier/pharmgkb/
n9http://linked.opendata.cz/resource/drugbank/drug/DB00259/identifier/wikipedia/

Statements

Subject Item
n2:DB00259
rdf:type
n3:Drug
n3:description
Sulfanilamide is a molecule containing the sulfonamide functional group attached to an aniline. [Wikipedia]
n3:dosage
n29:271B4191-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Nzila A: Inhibitors of de novo folate enzymes in Plasmodium falciparum. Drug Discov Today. 2006 Oct;11(19-20):939-44. Epub 2006 Sep 7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16997145
n3:group
approved
n3:indication
For the treatment of vulvovaginitis caused by <i>Candida albicans</i>.
n3:manufacturer
n5:271B418D-363D-11E5-9242-09173F13E4C5 n5:271B418C-363D-11E5-9242-09173F13E4C5
owl:sameAs
n28:DB00259 n30:DB00259
dcterms:title
Sulfanilamide
adms:identifier
n9:Sulfanilamide n12:SAN n13:PA451545 n15:C07458 n16:66663-103-04 n17:5333 n18:46508306 n19:10857 n20:DB00259 n21:9333 n22:5142
n3:mechanismOfAction
Sulfanilamide is a competitive inhibitor of bacterial enzyme dihydropteroate synthetase. This enzyme normally uses para-aminobenzoic acid (PABA) for synthesizing the necessary folic acid. The inhibited reaction is normally necessary in these organisms for the synthesis of folic acid. Without it, bacteria cannot replicate.
n3:packager
n5:271B418B-363D-11E5-9242-09173F13E4C5 n5:271B4189-363D-11E5-9242-09173F13E4C5 n5:271B418A-363D-11E5-9242-09173F13E4C5 n5:271B4187-363D-11E5-9242-09173F13E4C5 n5:271B4188-363D-11E5-9242-09173F13E4C5
n3:synonym
P-Aminobenzenesulfamide Streptocide Prontosil album Sulphanilamide Para-aminobenzenesulfonamide SA Sulfamine Sulfanilamide 4-Azanylbenzenesulfonamide 4-Aminobenzene sulfonic acid amide P-Aminobenzenesulfonamide
n3:toxicity
Oral, mouse LD<sub>50</sub> = 3700 mg/kg; Intravenous, mouse LD<sub>50</sub> = 621 mg/kg; Oral, rabbit LD<sub>50</sub> = 1300 mg/kg. Side effects include itching, burning, skin rash, redness, swelling, or other sign of irritation not present before use of this medicine and long-term use of sulfonamides may cause cancer of the thyroid gland.
n10:hasAHFSCode
n14:92-02-00%2A
n3:synthesisReference
Donald R. Randell, Emyr Phillips, "Anthraquinone sulphonamide compounds and preparation." U.S. Patent US4276224, issued May, 1937.
n24:hasConcept
n25:M0112101
foaf:page
n7:sulfanilamide.html
n3:IUPAC-Name
n4:271B4196-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B419C-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B419B-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4198-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4199-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B419A-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B4194-363D-11E5-9242-09173F13E4C5 n4:271B41AC-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B4195-363D-11E5-9242-09173F13E4C5 n4:271B4192-363D-11E5-9242-09173F13E4C5 n4:271B41AE-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B4193-363D-11E5-9242-09173F13E4C5 n4:271B41AF-363D-11E5-9242-09173F13E4C5
n3:pKa
n4:271B41B0-363D-11E5-9242-09173F13E4C5
n10:hasATCCode
n11:J01EB06 n11:D06BA05
n3:H-Bond-Acceptor-Count
n4:271B41A2-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B41A3-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B419D-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B419E-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B41A0-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B419F-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B41A1-363D-11E5-9242-09173F13E4C5
n3:absorption
Sulfonamides are absorbed through the vaginal mucosa. There are no pharmacokinetic data available describing how much of an intravaginal dose reaches the systemic circulation.
n3:affectedOrganism
Candida albicans and other yeasts
n3:casRegistryNumber
63-74-1
n3:category
n3:containedIn
n26:271B418F-363D-11E5-9242-09173F13E4C5 n26:271B4190-363D-11E5-9242-09173F13E4C5 n26:271B418E-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B41A8-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B41AA-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B41AB-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B41AD-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B41A7-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B41A6-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B41A9-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B4197-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B41A4-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B41A5-363D-11E5-9242-09173F13E4C5